Zhe Jiang Jian Feng Group Co Ltd

Chart & Performance

D1W1MN

P/E

45.42

P/S

1.71

EPS

0.26

Div Yield, %

0.84%

Shrs. gr., 5y

3.71%

Rev. gr., 5y

-4.11%

Revenues

2.88b

-0.58%

Net income

108m

+15.18%

CFO

412m

+497.42%

Dividend

Jul 16, 20240.1 CNY/sh

Profile

Zhejiang Jianfeng Group Co., Ltd. operates in the cement business in China. The company offers ordinary Portland and Portland slag cement products. It also provides pharmaceutical products, including aspartic acid amlodipine tablets for hypertension; heart pills for high blood pressure, dizziness, headache, neck pain, coronary heart disease, angina, nervous headache, and early sudden deafness; paroxetine hydrochloride tablets for various types of anxiety related with depression; vinegar acid chloride Finn zyban products for symptoms caused by osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; spray vial products for severe herpes zoster patients; and sodium hyaluronate eye drops for dry eyes. In addition, the company offers cable products, such as BV line common insulated and household electric wires; HYA series, which are copper core, solid polyolefin insulation block, and communications cables; network lines; RVV series cable mains; and SYWV-75 series physical foaming cables, as well as telecommunication cables. Further, it provides health products comprising boiling Jade Kim tea bags, bomb sugar, Sangge tea, lyophilized Tianma pieces, and broken fungus spore powder, as well as grape seed extract soft, Tianfu, vitamin E nutritional, bone Thai, and goodnight capsules. Additionally, the company offers warehousing and logistics services. It provides products and services through its marketing and sales channels. The company was founded in 1958 and is based in Jinhua, China.

URL

http://www.jianfeng.com.cn

IPO date

Jul 28, 1993

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues	2,876,477 -0.58%	2,893,369 -18.73%	3,560,394 -6.43%
Cost of revenue	2,484,060	2,591,158	3,084,435
Unusual Expense (Income)
NOPBT	392,417	302,211	475,959
NOPBT Margin	13.64%	10.44%	13.37%
Operating Taxes	68,671	43,680	104,590
Tax Rate	17.50%	14.45%	21.97%
NOPAT	323,746	258,531	371,369
Net income	107,988 15.18%	93,756 -67.41%	287,720 -68.86%
Dividends	(53,827)	(67,096)	(172,042)
Dividend yield	1.28%	1.77%	3.92%
Proceeds from repurchase of equity
BB yield
Debt
Debt current	196,156	167,500	467,751
Long-term debt	33,634	354,051	25,998
Deferred revenue	42,323	47,252	42,295
Other long-term liabilities	179,967	59,297	98,325
Net debt	(2,311,500)	(2,094,032)	(2,390,426)
Cash flow
Cash from operating activities	412,106	68,981	383,330
CAPEX	(338,833)	(237,463)
Cash from investing activities	(257,960)	(222,381)
Cash from financing activities	(110,182)	(33,312)	43,495
FCF	487,288	165,669	230,487
Balance
Cash	264,292	211,279	373,161
Long term investments	2,276,998	2,404,305	2,511,014
Excess cash	2,397,466	2,470,915	2,706,156
Stockholders' equity	4,921,344	4,862,244	5,369,832
Invested Capital	3,569,445	3,623,689	3,434,165
ROIC	9.00%	7.33%	11.45%
ROCE	6.57%	4.96%	7.75%
EV
Common stock shares outstanding	412,901	344,084	344,084
Price	10.15 -7.98%	11.03 -13.42%	12.74 -30.31%
Market cap	4,190,943 10.43%	3,795,245 -13.42%	4,383,628 -30.31%
EV	2,224,000	2,060,249	2,392,873
EBITDA	668,761	525,686	677,306
EV/EBITDA	3.33	3.92	3.53
Interest	25,076	19,020	16,569
Interest/NOPBT	6.39%	6.29%	3.48%